Candesartan may prevent aneurysmal changes in the residual native aorta after thoracic aortic aneurysm surgery

Trial Profile

Candesartan may prevent aneurysmal changes in the residual native aorta after thoracic aortic aneurysm surgery

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Jan 2013

At a glance

  • Drugs Candesartan cilexetil (Primary) ; Antihypertensives
  • Indications Aortic aneurysm
  • Focus Therapeutic Use
  • Acronyms CAPTAIN
  • Most Recent Events

    • 22 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top